Abstracts tagged "Proteoglycan"

Abstract Number: 1798 • ACR Convergence 2025
Proteomic Profiling of Chondrogenic Gene Therapy in Human MSCs Reveals Distinct Regenerative Pathways for Articular Cartilage Repair
Patricia Quaranta¹, Jagadeesh K Venkatesan², Valentina Calamia³, Patricia Fernández-Puente⁴, francisco J Blanco⁵, Magali Cucchiarini² and Cristina Ruiz-Romero⁶, ¹Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruna, Spain, ²Center of Experimental Orthopaedics, Saarland University and Saarland University Medical Center, Homburg, Germany, ³INIBIC, A Coruña, Spain, ⁴Instituto de Investigacion Biomedica de A Coruna (INIBIC), coruña, Spain, ⁵INIBIC-University of A Coruña, A Coruña, Galicia, Spain, ⁶Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain
Background/Purpose: Rheumatic diseases are characterized by pain and a progressive loss of joint function. Classical treatments alleviate pain symptoms but fail to fully repair sites…
Abstract Number: 0799 • ACR Convergence 2025
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].